Articoli con mandati relativi all'accesso pubblico - Mikko NiemiUlteriori informazioni
Non disponibili pubblicamente: 5
Role of cytochrome P450 2C8 in drug metabolism and interactions
JT Backman, AM Filppula, M Niemi, PJ Neuvonen
Pharmacological reviews 68 (1), 168-241, 2016
Mandati: Academy of Finland
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
M Niemi, KT Kivistö, U Diczfalusy, K Bodin, L Bertilsson, MF Fromm, ...
Pharmacogenetics and genomics 16 (8), 565-568, 2006
Mandati: German Research Foundation
Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone
MK Itkonen, A Tornio, M Neuvonen, PJ Neuvonen, M Niemi, JT Backman
Drug Metabolism and Disposition 44 (8), 1364-1371, 2016
Mandati: Academy of Finland
Clopidogrel carboxylic acid glucuronidation is mediated mainly by UGT2B7, UGT2B4, and UGT2B17: implications for pharmacogenetics and drug-drug interactions
H Kahma, AM Filppula, M Neuvonen, EK Tarkiainen, A Tornio, ...
Drug Metabolism and Disposition 46 (2), 141-150, 2018
Mandati: Academy of Finland
Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides
CC Orozco, M Neuvonen, YA Bi, MA Cerny, S Mathialagan, L Tylaska, ...
Molecular Pharmaceutics 20 (6), 3020-3032, 2023
Mandati: European Commission
Disponibili pubblicamente: 60
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update
LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ...
Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014
Mandati: US National Institutes of Health, Swedish Research Council, European Commission
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy
RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ...
Clinical Pharmacology & Therapeutics 92 (1), 112-117, 2012
Mandati: US National Institutes of Health, Swedish Research Council
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal …
RM Cooper‐DeHoff, M Niemi, LB Ramsey, JA Luzum, EK Tarkiainen, ...
Clinical Pharmacology & Therapeutics 111 (5), 1007-1021, 2022
Mandati: US National Institutes of Health, European Commission
International Transporter Consortium commentary on clinically important transporter polymorphisms
KM Giacomini, PV Balimane, SK Cho, M Eadon, T Edeki, KM Hillgren, ...
Clinical Pharmacology & Therapeutics 94 (1), 23-26, 2013
Mandati: US National Institutes of Health
Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation
A Tornio, AM Filppula, M Niemi, JT Backman
Clinical Pharmacology & Therapeutics 105 (6), 1345-1361, 2019
Mandati: Academy of Finland, European Commission
Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial
A Dicko, JM Brown, H Diawara, I Baber, A Mahamar, HM Soumare, ...
The Lancet Infectious Diseases 16 (6), 674-684, 2016
Mandati: Bill & Melinda Gates Foundation, US National Institutes of Health, UK …
Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel
MK Itkonen, A Tornio, O Lapatto‐Reiniluoto, M Neuvonen, PJ Neuvonen, ...
Clinical Pharmacology & Therapeutics 105 (1), 219-228, 2019
Mandati: Academy of Finland
Vegan diet in young children remodels metabolism and challenges the statuses of essential nutrients
T Hovinen, L Korkalo, R Freese, E Skaffari, P Isohanni, M Niemi, ...
EMBO molecular medicine 13 (2), e13492, 2021
Mandati: Academy of Finland
Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics
M Santos, M Niemi, M Hiratsuka, M Kumondai, M Ingelman-Sundberg, ...
Genetics in Medicine 20 (6), 622-629, 2018
Mandati: Swedish Research Council, European Commission, Government of Spain
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8
CL Aquilante, M Niemi, L Gong, RB Altman, TE Klein
Pharmacogenetics and genomics 23 (12), 721-728, 2013
Mandati: US National Institutes of Health
Transporter‐mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate
I Ali, JR Slizgi, JD Kaullen, M Ivanovic, M Niemi, PW Stewart, AS Barritt IV, ...
Clinical Pharmacology & Therapeutics 104 (4), 749-756, 2018
Mandati: US National Institutes of Health
Comparative hepatic and intestinal efflux transport of statins
F Deng, SK Tuomi, M Neuvonen, P Hirvensalo, S Kulju, C Wenzel, ...
Drug Metabolism and Disposition 49 (9), 750-759, 2021
Mandati: European Commission
Pharmacogenetics of bleeding and thromboembolic events in direct oral anticoagulant users
J Lähteenmäki, AL Vuorinen, J Pajula, K Harno, M Lehto, M Niemi, ...
Clinical Pharmacology & Therapeutics 110 (3), 768-776, 2021
Mandati: Business Finland
Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children
BP Gonçalves, H Pett, AB Tiono, D Murry, SB Sirima, M Niemi, T Bousema, ...
Antimicrobial agents and chemotherapy 61 (5), 10.1128/aac. 02590-16, 2017
Mandati: Bill & Melinda Gates Foundation, European Commission
Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials
GJH Bastiaens, AB Tiono, J Okebe, HE Pett, SA Coulibaly, BP Gonçalves, ...
PLoS One 13 (1), e0190272, 2018
Mandati: Bill & Melinda Gates Foundation, Department of International Development, UK …
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software